Recurrent Arterial and Venous Thrombotic Events in a Patient with Psoriasis. Impact of PAI-1 Polymorphism: A Case Report

1. Azfar R, Gelfand J. Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20(4):416-22.10.1097/BOR.0b013e3283031c99374649418525354Search in Google Scholar

2. Friedewald E, Cather C, Gelfand M, Gordon B, Gibbons H, Grundy S. AJCeditor's consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008;102(12):1631-43.10.1016/j.amjcard.2008.10.00419064017Search in Google Scholar

3. Goldhaber S. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56(1):1-7.10.1016/j.jacc.2010.01.05720620709Search in Google Scholar

4. Machlus K, Aleman M, Wolberg A. Update on venous thromboembolism: risk factors, mechanisms, and treatments. Arterioscler Thrombb Vasc Biol. 2011;31(3):476-8.10.1161/ATVBAHA.111.223008304443621325668Search in Google Scholar

5. Holst A, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010;121:1896-903.10.1161/CIRCULATIONAHA.109.92146020404252Search in Google Scholar

6. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Eubom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225-30.10.1023/B:EJEP.0000020447.59150.f9Search in Google Scholar

7. Reitsma P,Versteeg H, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 2012;32(3):563-8.10.1161/ATVBAHA.111.24281822345594Search in Google Scholar

8. Kimball A, Gladman D, Gelfand J, Gordon K, Horn E, Korman N, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations forscreening. J Am Acad Dermatol . 2008;58(6):1031-42.10.1016/j.jaad.2008.01.006371638218313171Search in Google Scholar

9. Komsa-Penkova R, Kovacheva-Kotseva K, Angelova S, Savov A, Simeonova M. [Selected methods of DNAanalysis and clinical applications]. 1st ed. Pleven: MU-Pleven; 2004. Bulgarian.Search in Google Scholar

10. Lutsey P, Prizment A, Folsom A. Psoriasis is associated withagreater risk of incident venous thromboembolism: the Iowa Women's Health Study. JTromb Haemost. 2012;10(4):708-11.10.1111/j.1538-7836.2012.04646.x331928222284895Search in Google Scholar

11. Karabudak O, Eralp R, Akyol A, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol. 2008;88(4):337-40.10.2340/00015555-0456Search in Google Scholar

12. Ko JH, Lin JW, Hui RC. Acute pulmonary embolism inapatient with hypereosinophilia and psoriasis. Chang Gung Med J. 2011;34(6):17-23.Search in Google Scholar

13.Vaughan D. PAI-1 and atherotrombosis. J Tromb Haemost. 2005;(8):1879-83.10.1111/j.1538-7836.2005.01420.x16102055Search in Google Scholar

14. Mehta R, Shapiro A. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008;14(6):1255-60.10.1111/j.1365-2516.2008.01834.xSearch in Google Scholar

15. Tsantes A, Nikolopoulos G, Bagos P, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5Gpolymorphism on the thrombotic risk. Thromb Res. 2008;122(6):736-42.10.1016/j.thromres.2007.09.005Search in Google Scholar

16. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 2007;12(8):2957-66.10.2741/2285Search in Google Scholar

17. Juhan-Vague I, Alessi MC, Mavri A, Morange P. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1(7):1575-9.10.1046/j.1538-7836.2003.00279.xSearch in Google Scholar

18. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. 2007;18(3):240-5.10.1097/MOL.0b013e32814e6d29Search in Google Scholar

19. Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P. Psoriasis and risk of venous thromboembolism:asystematic review and meta-analysis. QJM. 2014;107(10):793-7.10.1093/qjmed/hcu073Search in Google Scholar

20. Catherine N, Chiu M. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119-32.Search in Google Scholar

21. Harpel P, Zhang X, Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr. 1996;126(4 Suppl):1285S-9S.10.1093/jn/126.suppl_4.1285SSearch in Google Scholar

22. Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A. Homocysteine and stroke: evidence onacausal link from mendelian randomisation. Lancеt. 2005;365(9455):224-32.10.1016/S0140-6736(05)70152-5Search in Google Scholar

23.Wakkee M, Thio H, Prens E, Sijbrands E, Neumann H. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190(1):1-9.10.1016/j.atherosclerosis.2006.07.01116942772Search in Google Scholar

24. Oh C, Das K, Gottlieb A. Treatment with antitumor necrosis factorα (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. JAm Acad Dermatol. 2000;42(5):829-30.10.1067/mjd.2000.10594810775863Search in Google Scholar

25. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2012;147:179-87. Search in Google Scholar